SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 287 filers reported holding SAGE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $643,000 | -5.7% | 8,908 | +83.2% | 0.02% | -8.7% |
| Q3 2019 | $682,000 | -24.6% | 4,863 | -1.6% | 0.02% | -23.3% |
| Q2 2019 | $905,000 | -74.0% | 4,941 | -77.4% | 0.03% | -73.2% |
| Q1 2019 | $3,479,000 | +69.0% | 21,875 | +1.8% | 0.11% | +55.6% |
| Q4 2018 | $2,059,000 | -56.4% | 21,491 | -35.7% | 0.07% | -48.2% |
| Q3 2018 | $4,724,000 | +21.0% | 33,442 | +34.1% | 0.14% | +19.8% |
| Q2 2018 | $3,904,000 | -14.8% | 24,938 | -12.3% | 0.12% | -26.1% |
| Q1 2018 | $4,580,000 | -3.5% | 28,433 | -1.3% | 0.16% | -2.5% |
| Q4 2017 | $4,744,000 | +246.8% | 28,803 | +31.1% | 0.16% | +242.6% |
| Q3 2017 | $1,368,000 | -58.6% | 21,964 | -47.0% | 0.05% | -62.1% |
| Q2 2017 | $3,301,000 | +72.8% | 41,446 | +54.2% | 0.12% | +77.1% |
| Q1 2017 | $1,910,000 | -38.8% | 26,871 | -56.1% | 0.07% | -34.6% |
| Q4 2016 | $3,122,000 | – | 61,142 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |